Foghorn Therapeutics Inc.

05/19/2022 | Press release | Distributed by Public on 05/19/2022 14:03

Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS